Floatz logo

p1446a-05

Advanced or Inoperable Malignant Melanoma With BRAF Mutation

Piramal Enterprises LimitedPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

450 Active assets in the Advanced or Inoperable Malignant Melanoma With BRAF Mutation cohort.

Asset / SponsorPhaseRating
Gm-Csf
Ultimovacs ASA
Phase 4BBB
Sargramostim
Mayo Clinic
Phase 3BBB
Cediranib
M.D. Anderson Cancer Center
Phase 3BBB
Ifa
Craig L Slingluff, Jr
Phase 2BB
Tebentafusp
Immunocore Ltd
Phase 3BB

View all 50 →

Same molecule, other indications

p1446a-05 is also rated in:

B-cell chronic lymphocytic leukemiaDormant
CC
Indicative ·
43 / 100
View asset →
hematopoietic and lymphoid cell neoplasmDormant
CC
Indicative ·
42 / 100
View asset →
neoplasmDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →